Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $42.50 | Total: $212.50 |
| 1 | 10 | $36.00 | Total: $360.00 |
| 1 | 25 | $30.50 | Total: $762.50 |
| 1 | 50 | $26.00 | Total: $1,300.00 |
| 1 | 100 | $22.50 | Total: $2,250.00 |
Overview
Avatrombopag (YM477) is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferationdifferentiation and platelet production.
Chemical Properties
| Molecular Formula | C29H34Cl2N6O3S2 |
| Molecular Weight | 649.65 |
| CAS Numbers | 570406-98-3 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1nc(-c2cc(Cl)cs2)c(s1)N1CCN(CC1)C1CCCCC1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Xu H, Cai R.Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease.Expert Rev Clin Pharmacol. 2019 Sep;12[9] 859-865